April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
PPAR-beta in Retinal Angiogenesis
Author Affiliations & Notes
  • J. S. Penn
    Vanderbilt Eye Institute, Vanderbilt Univ Schl of Med, Nashville, Tennessee
  • G. W. McCollum
    Vanderbilt Eye Institute, Vanderbilt Univ Schl of Med, Nashville, Tennessee
  • S. E. Yanni
    Vanderbilt Eye Institute, Vanderbilt Univ Schl of Med, Nashville, Tennessee
  • M. S. Assadian
    Vanderbilt Eye Institute, Vanderbilt Univ Schl of Med, Nashville, Tennessee
  • R. Yang
    Vanderbilt Eye Institute, Vanderbilt Univ Schl of Med, Nashville, Tennessee
  • Footnotes
    Commercial Relationships  J.S. Penn, None; G.W. McCollum, None; S.E. Yanni, None; M.S. Assadian, None; R. Yang, None.
  • Footnotes
    Support  NIH Grant EY07533; Research to Prevent Blindness
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2958. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. S. Penn, G. W. McCollum, S. E. Yanni, M. S. Assadian, R. Yang; PPAR-beta in Retinal Angiogenesis. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2958.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Peroxisome proliferator-activated receptors (PPARs) are nuclear membrane receptors that exist as three subtypes - a, b and g. PPARs are activated by a number of ligands, including naturally occurring fatty acids, NSAIDs, and prostaglandins. Of the three PPAR subtypes, PPAR-b appears to play a role in cell proliferation. The purpose of this study was to determine whether PPAR-b is pro-angiogenic in the retina.

Methods: : In vitro, retinal Müller cells were subjected to normoxia or hypoxia for 24 hrs. Retinal microvascular endothelial cells (RMEC) were treated with and without VEGF for 24 hrs. Microarray analysis of PPAR-b-related genes was performed. Müller cells were treated with a PPAR-b inhibitor, sulindac sulfide (SS), or with siRNA directed against PPAR-b, and hypoxia-induced VEGF production was measured. RMEC were treated with SS, or with PPAR-b-directed siRNA, and VEGF-induced proliferation and tube formation were measured. RMEC were treated with cPGI, a stable analog of PGI2 (a known ligand for PPAR-b), and PPAR-b activation was measured. In vivo, rats were subjected to OIR, treated with SS, and neovascular (NV) area was measured.

Results: : Hypoxic Müller cells and VEGF-treated RMEC demonstrated a significant increase (p = 0.01) in PPAR-b expression. Expression of adipose differentiation-related protein (ADRP), a protein exclusively regulated by PPAR-b, demonstrated a 6-fold increase in hypoxic Müller cells. SS and PPAR-b-directed siRNA resulted in dose-dependent inhibition of hypoxia-induced VEGF production in Müller cells and VEGF-induced proliferation (p= 0.005) and tube formation in RMEC. RMEC treated with cPGI demonstrated a 3.5-fold increase in PPAR-b activation, measured by ADRP expression. In OIR rats, SS demonstrated a dose-dependent reduction in NV area that reached 50%.

Conclusions: : In vitro, inhibiting PPAR-b led to both an inhibition of Müller cell and RMEC angiogenic cell behaviors, suggesting that it may play multiple roles in regulating angiogenesis. In vivo, PPAR-b inhibition reduced pathological retinal NV. These findings suggest that PPAR-b may constitute a novel and rational target for chemotherapeutic intervention in ocular angiogenesis.

Keywords: retinal neovascularization • transcription factors • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×